February 2nd 2023
Closing out their discussion on myeloproliferative neoplasms, key opinion leaders share excitement for future evolutions in the treatment paradigm.
January 26th 2023
Following their overview on novel treatment modalities in myeloproliferative neoplasms, expert panelists consider how best to sequence and manage novel therapies in practice.
A broad and comprehensive review of novel targeted agents under investigation in the setting of myeloproliferative neoplasm management.
January 19th 2023
Key opinion leaders on myeloproliferative neoplasms review the potential of CALR as a therapeutic target following data from the ASH 2022 Annual Meeting.
Expert panelists consider the ongoing role of transplant for patients with myelofibrosis and discuss when it is more appropriate to explore systemic therapy options.
January 12th 2023
Closing out their discussion on the management of myelofibrosis, panelists highlight updated data with fedratinib and ruxolitinib, respectively.
A brief review of the biology of myelofibrosis, the potential for disease modification, and subsequent implications for treatment.
January 5th 2023
Key opinion leaders on myeloproliferative neoplasms review clinical data behind pacritinib therapy in the setting of myelofibrosis.
Switching their focus to myelofibrosis management, expert panelists reflect on clinical data behind momelotinib, a novel JAK2 inhibitor.
December 22nd 2022
Shared insight on how a patient’s symptom burden can impact management strategies within essential thrombocytopenia and polycythemia vera.
Expert perspectives on the respective treatment landscapes of essential thrombocytopenia (ET) and polycythemia vera (PV) following the ASH 2022 Annual Meeting.
December 19th 2022
Jeanne M. Palmer, MD, discusses total symptom scores in patients with myelofibrosis with thrombocytopenia.
August 24th 2022
The panelists conclude their discussion by highlighting investigational agents to look forward to.
Rami Komrokji, MD, presents to the panel a second clinical scenario of a 74-year-old with cytopenic myelofibrosis.
August 18th 2022
A look at the potential treatment options for a patient with myelofibrosis who progresses after first-line therapy.
Key opinion leaders discuss how they would approach treating a 67-year-old with myelofibrosis, presenting with splenomegaly.
August 11th 2022
Drs Palmer and Mesa explain the challenges of treating accelerated phase myeloproliferative neoplasms.
The panel reviews other exciting novel agents under investigation for myelofibrosis treatment.
Ruben Mesa, MD, discusses updates on the novel agent momelotinib from an abstract he presented at ASCO 2022.
Jamile Shammo, MD, FACP, explains the efficacy and safety of the 3 approved therapies for myelofibrosis.